Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (June 2011)
30 slides from Genetic Technologies's investor presentation, Jun 6, 2011
Slide 1: Genetic Technologies Limited
For personal use only GENETIC TECHNOLOGIES LIMITED (GENE:NASDAQ, GTG:ASX) June 2011
Slide 2: Forward Looking Statements
For personal use only Forward Looking Statements This presentation may contain forward‐looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach
Slide 3: Introduction
For personal use only Introduction Currently in the 2nd year of a 5 year strategy to build a global cancer diagnostics business BREVAGen™ is the first product in this expansion June 2011 launch in US Breast cancer risk test – buccal (cheek) swab 80%+ gross margins and $600m pa addressable
Slide 4: Investment Snapshot
For personal use only Investment Snapshot Strong execution record: Clear focus on cancer diagnostics growth Demonstrated M&A capability Cash flow +ve and profitable H1 due to increased revenues and cost reductions Achievement of Australia’s first CLIA certification Establishment of US sa
Slide 5: Established Genetic Testing Business
For personal use only Established Genetic Testing Business Dominant market positions PacRim Globally accredited laboratory Experience producing & selling genetic tests Oncology testing Australia, Asia & EU Contracted provider to NSW Police Force for volume crime forensic testing 50+% mar
Slide 6: Licensing: Non-Dilutive Funding Source
For personal use only Licensing: Non‐Dilutive Funding Source Non‐coding DNA patent estate is one of GTG’s core assets $65m+ licensing revenue received to date 9 Licenses granted FY2011 to date for total $14.2m Contracted annuity stream of $7m in total to 2015 Foundational patent families p
Slide 7: Industry Scope and Available Markets
For personal use only Industry Scope and Available Markets `179 INTRON SEQUENCE ANALYSIS AGRIGENETICS TRAIT SELECTION LABS GENOMIC MAPPING IVDs EQUIPMENT NON-CODING PATENTS SEQUENCING PHARMA EQUIPMENT COMPANIES `179 Licensed AGRIGENETICS GWAS `762 Licensed `762 GENOMIC Unlicensed MAPPING
Slide 8: Patent Assertion Program
For personal use only Patent Assertion Program IP assertion program with off balance sheet funding Sheridan Ross in Denver driving legals 1st suit filed Feb 2010 All 9 parties settled prior to trial for total of over $5 million 2nd suit filed Jan 2011 All but one party in settlement disc
Slide 9: Cancer Diagnostics Focus
For personal use only Cancer Diagnostics Focus New technologies driving personalized medicine & extending lives Molecular diagnosis of cancer is most attractive segment of diagnostics industry Focused market & efficient sales process Accelerating growth forecast next 4 years US & EU market
Slide 10: Portfolio Strategy
For personal use only Portfolio Strategy G1 In validation 2005 launch G2 in development KRas BRaf EGFR Q2 CY11 US launch Feb ’10 launch May ’10 launch Developing a portfolio of tools across cancer management spectrum in top 6 cancers Developing &/or acquiring products with global protection, app
Slide 11: BREVAGen™
For personal use only BREVAGen™ Novel, validated test for non‐familial breast cancer risk US$600m per annum market opportunity Attractive gross margin ‐ buccal swab Preparing to launch in 8 US territories Q2 CY11 High profile Key Opinion Leaders involved Experts at Stanford, Sloane‐Kette
Slide 12: BREVAGen™: What does it Mean Clinically?
For personal use only BREVAGen™: What does it Mean Clinically? BREVAGen™ test classifies a woman’s 5 year & lifetime risk of non‐familial breast cancer, the commonest variety Test combines population risk factors with 7 genetic biomarkers (SNPs) to give an integrated, individual breast cancer ri
Slide 13: The BREVAGen™ GWAS studies
For personal use only The BREVAGen™ GWAS studies Stage (1) 266,722 SNPs Used to tag common variants across the genome Genotyped: 408 breast cancer cases 400 controls Stage (2) 12,711 SNPs (approx 5% of those typed in stage (1)) Genotyped: 3,990 invasive breast cancer cases 3,916 controls Stage (3) 3
Slide 14: BREVAGen™ performance for risk prediction
For personal use only BREVAGen™ performance for risk prediction Mealiffe ME, et al., Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information; (2010). Journal of the National Cancer Institute 102: 1‐10. 1. BREVAGen™ risk reclassification results from 3
Slide 15: BREVAGen™ – Fits Into Existing ASCO & ACS Guidelines
BREVAGen™ – Fits Into Existing ASCO & ACS For personal use only Positive mammogram Breast Cancer Management Guidelines 1.6m breast biopsy patients pa (US) 65% or 1m patients at intermediate risk due abnormal pathology Preventive therapy can prevent 50-70% cancers if targeted via BREVAGen™ Analysis r
Slide 16: Genetics of Breast Cancer Risk
For personal use only Genetics of Breast Cancer Risk Genes can either be detected as: Mutations (such as BRCA) or Single nucleotide polymorphisms (such as those in BREVAGen™), indicating a Non‐familial (BREVAGen higher breast cancer risk market) 80% BRCA testing sales are Hereditary (BRCA ma
Slide 17: Target Patient Groups
Target Patient Groups Target market build For personal use only Initial target market 1,521 High Value MD/OBGYNs with high numbers of BRCA patient tests identified 80‐90% of BRCA results are negative, 200‐300k patients pa Second target market Mammograms 1m atypical biopsy patients pa 1.6m br
Slide 18: National View of the Initial Territories
National View of the 8 Initial Territories Selected on the basis of: For personal use only CLIA status - Reimbursement ease - Patient clustering 18
Slide 19: BREVAGen™ Rest of World
For personal use only BREVAGen™ Rest of World Substantial additional opportunities exist in Europe and PacRim Some re‐calibration of algorithm needed for European populations Status of existing dossier would enable reasonably rapid CE marking once label claim adjusted Assessment of initial E
Slide 20: Established Facilities
For personal use only Established Facilities Genetic Technologies Ltd Fitzroy, VIC, Australia Technical & corporate support and globally accredited sample processing. CLIA certified. Phenogen Sciences Inc Charlotte, North Carolina, USA Sales & marketing, customer support, reimbursement mgt and sampl
Slide 21: Competitors
For personal use only Competitors deCODE (Iceland) Launched in October 2008 by deCODE Genetics, no validation deCODE Breast Cancer test assesses risk based on 7 common SNPs, ordered only via MDs. Price = $1,650 Emerged from Chapter 11 in April 2010 as a private company – no US presence since
Slide 22: Execution Capability & Monitoring
For personal use only Execution Capability & Monitoring Quantitative Strategic Risk Register allows monitoring, measurement and reporting of key success factors Developed with assistance from Marsh Risk Consulting Items tracked and managed include: KOL development Medical marketing success
Slide 23: Benchmarking and Key Success Factors
For personal use only Benchmarking and Key Success Factors Benchmarking against more advanced peers: 1. CLIA approval 3 2. Pharmacoeconomic analysis 3 Market Cap: $742M 3. Consistent with treatment guidelines 3 Revenue $175M Sales Force: 88 4. KOL’s and speaker programs 3 Key Product: Oncotype Dx
Slide 24: Management Expertise
For personal use only Management Expertise Dr. Paul MacLeman CEO Tom Howitt, International diagnostics, Chief Finance Officer therapeutics 20 years of expertise in public Co. governance commercialization and investment banking and capital raising experience and expertise Dr. David Sparling Lewis Stu
Slide 25: Product Portfolio
For personal use only Product Portfolio Target Discovery Clinical Regulatory and Validation Review Launch and Selection Studies or CLIA Release Marker Clinical Launch Claim Validation Utility Planning Extension Studies & Studies Publication BRCA/HNPCC/SCN1A (EU/PacRim) BREVAGEN™ KRAS/BRAF/EGFR (FPFE
Slide 26: Portfolio Revenue Growth
For personal use only Portfolio Revenue Growth BREVAGen™ the first Collaboration with multi‐ global product in the national pharmaco cancer diagnostics strategy Followed by introduction of generic theranostic markers late Y1 Blood based Y2 introduction of KRAS series blood based G2 BREVAGen
Slide 27: M&A
M&A GTG acquired and integrated BREVAGen™ as a market ready For personal use only asset 2010 MDx assets are currently cheaper to buy than make Actively assessing new late stage/on‐market product acquisitions. Seeking: On or close to market assets Similar sales channels and marketing synerg
Slide 28: Financial Snapshot Mar 2011
For personal use only Financial Snapshot Mar 2011 Financials (9 months to Mar 31) Share Register (AUD millions) 2011 2010 Shares outstanding 404.6m Revenue 16.1 6.2 Top 20 shareholders 76% Operations* 3.3 4.2 Total shareholders 2,850 Licensing 12.8 2.0 Options outstanding ** 17.3m Net income / (
Slide 29: Summary
For personal use only Summary GTG to launch world’s first validated test for non‐ familial breast cancer risk BREVAGen™ has attractive CoGS & rapid payback Target market is global, characterized & large US sales, marketing & reimbursement infrastructure established GTG has a sound base of
Slide 30: Contact Details
For personal use only Contact Details Dr Paul D R MacLeman CEO Genetic Technologies Limited Direct Phone +61 3 8412 7025 Cell +61 419 401 445 (Aust.) (980) 253 4340 (US) Email paul.macleman@gtglabs.com 30
Genetic Technologies — Investor Presentation (June 2011) on 6ix